

Special Issue

Multi-Omics, Bioinformatics & Cancers

Message from the Guest Editor

Tumors showcase a wide range of genetic changes influencing their initiation, growth, and progression, with these mutations granting advantages leading to immune evasion and therapy resistance.

Understanding how specific tumor mutations contribute to immune evasion is crucial for effective immunotherapies.

Targeted therapies have transformed cancer treatment, inhibiting key signaling pathways. Yet, resistance, often involving immune evasion mechanisms, poses a challenge. Exploring the crosstalk between immune evasion and targeted therapy resistance unveils complex adaptive responses, guiding the development of combination strategies.

This Special Issue delves into cutting-edge research, exploring therapeutic approaches that exploit the interplay between tumor mutations, immune evasion, and targeted therapy resistance using bioinformatics and multi-omics approaches. We welcome diverse contributions, including those investigating tumor mutational processes' impact on immune recognition, overcoming therapy resistance, and therapeutic modulation of the tumor immune microenvironment.

Guest Editor

Dr. Shanye Yin

Department of Pathology, Albert Einstein College of Medicine, Bronx, NY, USA

Deadline for manuscript submissions

closed (15 June 2024)

G C A T
T A C G
G C A T

Genes

an Open Access Journal
by MDPI

Impact Factor 2.8
CiteScore 5.5
Indexed in PubMed



mdpi.com/si/192455

Genes
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
genes@mdpi.com

[mdpi.com/journal/
genes](https://mdpi.com/journal/genes)



G C A T
T A C G
G C A T

Genes

an Open Access Journal
by MDPI

Impact Factor 2.8
CiteScore 5.5
Indexed in PubMed



[mdpi.com/journal/
genes](https://mdpi.com/journal/genes)



About the Journal

Message from the Editor-in-Chief

Genes is central to our understanding of biology, and modern advances such as genomics and genome editing have maintained genetics as a vibrant, diverse and fast-moving field. There is a need for good quality, open access journals in this area, and the *Genes* team aims to provide expert manuscript handling, serious peer review, and rapid publication across the whole discipline of genetics. Starting in 2010, the journal is now well established and recognised. Why not consider *Genes* for your next genetics paper?

Editor-in-Chief

Prof. Dr. Selvarangan Ponnazhagan
Department of Pathology, The University of Alabama at Birmingham,
1825 University Blvd, SHEL 814, Birmingham, AL 35294-2182, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, PubAg, and other databases.

Journal Rank:

JCR - Q2 (Genetics and Heredity) / CiteScore - Q2 (Genetics (clinical))